THE VIEW FROM MANAGED CARE PHARMACY

This stratified, national telephone survey of fifty-one managed care o rganizations concerns the perspectives of managed care pharmacy direct ors on pharmacoeconomics, disease management, and the roles of the pha rmaceutical industry and the Food and Drug Administration (FDA). Respo ndents rated clinical effectiveness assessments as most useful, cost-e ffectiveness assessments second, and quality-of-life assessments as le ast useful. Peer-reviewed and industry literature were rated as equall y important for decision making, Most plans would consider establishin g a partnership with a drug company for disease management, if they ha ve not already done so. Most plans (76 percent) support some form of F DA regulation of pharmacoeconomic claims. Conversely, 69 percent favor either no regulation (24 percent) or less stringent regulation (45 pe rcent) than exists today.